APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gefitinib

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Gefitinib Industry Growth and Trends Forecast to 2032

23 December 2025122 pages

Choose your research edition.

Industry ResearchGefitinib Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Gefitinib Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Gefitinib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gefitinib Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Gefitinib Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Gefitinib market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Gefitinib is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Gefitinib is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gefitinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Gefitinib include Qilu Pharmaceutical, AstraZeneca, Zuventus Healthcare, United Biotech, Sichuan Xieli Pharmaceutical, Panacea Biotec, Nobel Ilac Sanayii Ve Ticaret, Nishchay Pharmaceuticals and Natco Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Gefitinib market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Gefitinib market size, estimates, and forecasts are presented in terms of sales volume (k pcs) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Gefitinib market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Gefitinib.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Gefitinib market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Gefitinib Market by Company

Qilu Pharmaceutical

AstraZeneca

Zuventus Healthcare

United Biotech

Sichuan Xieli Pharmaceutical

Panacea Biotec

Nobel Ilac Sanayii Ve Ticaret

Nishchay Pharmaceuticals

Natco Pharma

Jodas Expoim

Hetero Drugs

Globela Pharma

Glenmark Pharmaceuticals

Flagship Biotech International

Ethypharm

Dr Reddy's Laboratories

Cipla

Celon Laboratories

Cadila Pharmaceuticals

Accure Labs

Gefitinib Segment by Type

10 Tables/Box

30 Tables/Box

90 Tables/Box

Gefitinib Segment by Application

Drug Center

Hospital

Clinic

Others

Gefitinib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gefitinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gefitinib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gefitinib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Gefitinib manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Gefitinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 10 Tables/Box Table 2. Major Company of 30 Tables/Box Table 3. Major Company of 90 Tables/Box Table 4. Global Gefitinib Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Gefitinib Sales by Type (2021-2026) & (k pcs) Table 6. Global Gefitinib Sales Market Share in Volume by Type (2021-2026) Table 7. Global Gefitinib Sales by Type (2021-2026) & (US$ Million) Table 8. Global Gefitinib Sales Market Share in Value by Type (2021-2026) Table 9. Global Gefitinib Price by Type (2021-2026) & (US$/pcs) Table 10. Global Gefitinib Sales by Type (2027-2032) & (k pcs) Table 11. Global Gefitinib Sales Market Share in Volume by Type (2027-2032) Table 12. Global Gefitinib Sales by Type (2027-2032) & (US$ Million) Table 13. Global Gefitinib Sales Market Share in Value by Type (2027-2032) Table 14. Global Gefitinib Price by Type (2027-2032) & (US$/pcs) Table 15. North America Gefitinib Sales by Type (2021-2026) & (k pcs) Table 16. North America Gefitinib Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Gefitinib Sales by Type (2021-2026) & (k pcs) Table 18. Europe Gefitinib Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Gefitinib Sales by Type (2021-2026) & (k pcs) Table 20. Asia-Pacific Gefitinib Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Gefitinib Sales by Type (2021-2026) & (k pcs) Table 22. Latin America Gefitinib Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Gefitinib Sales by Type (2021-2026) & (k pcs) Table 24. Middle East and Africa Gefitinib Sales by Type (2021-2026) & (US$ Million) Table 25. Gefitinib Industry Trends Table 26. Gefitinib Industry Drivers Table 27. Gefitinib Industry Opportunities and Challenges Table 28. Gefitinib Industry Restraints Table 29. Global Gefitinib Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Gefitinib Revenue Market Share by Company (2021-2026) Table 31. Global Gefitinib Sales by Company (2021-2026) & (k pcs) Table 32. Global Gefitinib Sales Share by Company (2021-2026) Table 33. Global Gefitinib Market Price by Company (2021-2026) & (US$/pcs) Table 34. Global Gefitinib Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Gefitinib Major Company Production Sites and Headquarters Table 36. Global Gefitinib Company, Product Type & Application Table 37. Global Gefitinib Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Gefitinib by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Gefitinib Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Gefitinib Sales by Region (2021-2026) & (k pcs) Table 42. Global Gefitinib Sales Market Share in Volume by Region (2021-2026) Table 43. Global Gefitinib Sales by Region (2021-2026) & (US$ Million) Table 44. Global Gefitinib Sales Market Share in Value by Region (2021-2026) Table 45. Global Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 46. Global Gefitinib Sales by Region (2027-2032) & (k pcs) Table 47. Global Gefitinib Sales Market Share in Volume by Region (2027-2032) Table 48. Global Gefitinib Sales by Region (2027-2032) & (US$ Million) Table 49. Global Gefitinib Sales Market Share in Value by Region (2027-2032) Table 50. Global Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2027-2032) Table 51. Global Gefitinib Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Gefitinib Sales by Application (2021-2026) & (k pcs) Table 53. Global Gefitinib Sales Market Share in Volume by Application (2021-2026) Table 54. Global Gefitinib Sales by Application (2021-2026) & (US$ Million) Table 55. Global Gefitinib Sales Market Share in Value by Application (2021-2026) Table 56. Global Gefitinib Price by Application (2021-2026) & (US$/pcs) Table 57. Global Gefitinib Sales by Application (2027-2032) & (k pcs) Table 58. Global Gefitinib Sales Market Share in Volume by Application (2027-2032) Table 59. Global Gefitinib Sales by Application (2027-2032) & (US$ Million) Table 60. Global Gefitinib Sales Market Share in Value by Application (2027-2032) Table 61. Global Gefitinib Price by Application (2027-2032) & (US$/pcs) Table 62. North America Gefitinib Sales by Application (2021-2026) & (k pcs) Table 63. North America Gefitinib Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Gefitinib Sales by Application (2021-2026) & (k pcs) Table 65. Europe Gefitinib Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Gefitinib Sales by Application (2021-2026) & (k pcs) Table 67. Asia-Pacific Gefitinib Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Gefitinib Sales by Application (2021-2026) & (k pcs) Table 69. Latin America Gefitinib Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Gefitinib Sales by Application (2021-2026) & (k pcs) Table 71. Middle East and Africa Gefitinib Sales by Application (2021-2026) & (US$ Million) Table 72. Qilu Pharmaceutical Company Information Table 73. Qilu Pharmaceutical Business Overview Table 74. Qilu Pharmaceutical Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 75. Qilu Pharmaceutical Gefitinib Product Portfolio Table 76. Qilu Pharmaceutical Recent Development Table 77. AstraZeneca Company Information Table 78. AstraZeneca Business Overview Table 79. AstraZeneca Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 80. AstraZeneca Gefitinib Product Portfolio Table 81. AstraZeneca Recent Development Table 82. Zuventus Healthcare Company Information Table 83. Zuventus Healthcare Business Overview Table 84. Zuventus Healthcare Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 85. Zuventus Healthcare Gefitinib Product Portfolio Table 86. Zuventus Healthcare Recent Development Table 87. United Biotech Company Information Table 88. United Biotech Business Overview Table 89. United Biotech Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 90. United Biotech Gefitinib Product Portfolio Table 91. United Biotech Recent Development Table 92. Sichuan Xieli Pharmaceutical Company Information Table 93. Sichuan Xieli Pharmaceutical Business Overview Table 94. Sichuan Xieli Pharmaceutical Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 95. Sichuan Xieli Pharmaceutical Gefitinib Product Portfolio Table 96. Sichuan Xieli Pharmaceutical Recent Development Table 97. Panacea Biotec Company Information Table 98. Panacea Biotec Business Overview Table 99. Panacea Biotec Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 100. Panacea Biotec Gefitinib Product Portfolio Table 101. Panacea Biotec Recent Development Table 102. Nobel Ilac Sanayii Ve Ticaret Company Information Table 103. Nobel Ilac Sanayii Ve Ticaret Business Overview Table 104. Nobel Ilac Sanayii Ve Ticaret Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 105. Nobel Ilac Sanayii Ve Ticaret Gefitinib Product Portfolio Table 106. Nobel Ilac Sanayii Ve Ticaret Recent Development Table 107. Nishchay Pharmaceuticals Company Information Table 108. Nishchay Pharmaceuticals Business Overview Table 109. Nishchay Pharmaceuticals Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 110. Nishchay Pharmaceuticals Gefitinib Product Portfolio Table 111. Nishchay Pharmaceuticals Recent Development Table 112. Natco Pharma Company Information Table 113. Natco Pharma Business Overview Table 114. Natco Pharma Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 115. Natco Pharma Gefitinib Product Portfolio Table 116. Natco Pharma Recent Development Table 117. Jodas Expoim Company Information Table 118. Jodas Expoim Business Overview Table 119. Jodas Expoim Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 120. Jodas Expoim Gefitinib Product Portfolio Table 121. Jodas Expoim Recent Development Table 122. Hetero Drugs Company Information Table 123. Hetero Drugs Business Overview Table 124. Hetero Drugs Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 125. Hetero Drugs Gefitinib Product Portfolio Table 126. Hetero Drugs Recent Development Table 127. Globela Pharma Company Information Table 128. Globela Pharma Business Overview Table 129. Globela Pharma Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 130. Globela Pharma Gefitinib Product Portfolio Table 131. Globela Pharma Recent Development Table 132. Glenmark Pharmaceuticals Company Information Table 133. Glenmark Pharmaceuticals Business Overview Table 134. Glenmark Pharmaceuticals Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 135. Glenmark Pharmaceuticals Gefitinib Product Portfolio Table 136. Glenmark Pharmaceuticals Recent Development Table 137. Flagship Biotech International Company Information Table 138. Flagship Biotech International Business Overview Table 139. Flagship Biotech International Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 140. Flagship Biotech International Gefitinib Product Portfolio Table 141. Flagship Biotech International Recent Development Table 142. Ethypharm Company Information Table 143. Ethypharm Business Overview Table 144. Ethypharm Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 145. Ethypharm Gefitinib Product Portfolio Table 146. Ethypharm Recent Development Table 147. Dr Reddy's Laboratories Company Information Table 148. Dr Reddy's Laboratories Business Overview Table 149. Dr Reddy's Laboratories Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 150. Dr Reddy's Laboratories Gefitinib Product Portfolio Table 151. Dr Reddy's Laboratories Recent Development Table 152. Cipla Company Information Table 153. Cipla Business Overview Table 154. Cipla Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 155. Cipla Gefitinib Product Portfolio Table 156. Cipla Recent Development Table 157. Celon Laboratories Company Information Table 158. Celon Laboratories Business Overview Table 159. Celon Laboratories Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 160. Celon Laboratories Gefitinib Product Portfolio Table 161. Celon Laboratories Recent Development Table 162. Cadila Pharmaceuticals Company Information Table 163. Cadila Pharmaceuticals Business Overview Table 164. Cadila Pharmaceuticals Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 165. Cadila Pharmaceuticals Gefitinib Product Portfolio Table 166. Cadila Pharmaceuticals Recent Development Table 167. Accure Labs Company Information Table 168. Accure Labs Business Overview Table 169. Accure Labs Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 170. Accure Labs Gefitinib Product Portfolio Table 171. Accure Labs Recent Development Table 172. North America Gefitinib Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 173. North America Gefitinib Sales by Country (2021-2026) & (k pcs) Table 174. North America Gefitinib Sales Market Share by Country (2021-2026) Table 175. North America Gefitinib Sales Forecast by Country (2027-2032) & (k pcs) Table 176. North America Gefitinib Sales Market Share Forecast by Country (2027-2032) Table 177. North America Gefitinib Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 178. North America Gefitinib Market Size by Country (2021-2026) & (US$ Million) Table 179. North America Gefitinib Market Share by Country (2021-2026) Table 180. North America Gefitinib Market Size Forecast by Country (2027-2032) & (US$ Million) Table 181. North America Gefitinib Market Share Forecast by Country (2027-2032) Table 182. Europe Gefitinib Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 183. Europe Gefitinib Sales by Country (2021-2026) & (k pcs) Table 184. Europe Gefitinib Sales Market Share by Country (2021-2026) Table 185. Europe Gefitinib Sales Forecast by Country (2027-2032) & (k pcs) Table 186. Europe Gefitinib Sales Market Share Forecast by Country (2027-2032) Table 187. Europe Gefitinib Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 188. Europe Gefitinib Market Size by Country (2021-2026) & (US$ Million) Table 189. Europe Gefitinib Market Share by Country (2021-2026) Table 190. Europe Gefitinib Market Size Forecast by Country (2027-2032) & (US$ Million) Table 191. Europe Gefitinib Market Share Forecast by Country (2027-2032) Table 192. Asia-Pacific Gefitinib Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 193. Asia-Pacific Gefitinib Sales by Country (2021-2026) & (k pcs) Table 194. Asia-Pacific Gefitinib Sales Market Share by Country (2021-2026) Table 195. Asia-Pacific Gefitinib Sales Forecast by Country (2027-2032) & (k pcs) Table 196. Asia-Pacific Gefitinib Sales Market Share Forecast by Country (2027-2032) Table 197. Asia-Pacific Gefitinib Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 198. Asia-Pacific Gefitinib Market Size by Country (2021-2026) & (US$ Million) Table 199. Asia-Pacific Gefitinib Market Share by Country (2021-2026) Table 200. Asia-Pacific Gefitinib Market Size Forecast by Country (2027-2032) & (US$ Million) Table 201. Asia-Pacific Gefitinib Market Share Forecast by Country (2027-2032) Table 202. Latin America Gefitinib Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 203. Latin America Gefitinib Sales by Country (2021-2026) & (k pcs) Table 204. Latin America Gefitinib Sales Market Share by Country (2021-2026) Table 205. Latin America Gefitinib Sales Forecast by Country (2027-2032) & (k pcs) Table 206. Latin America Gefitinib Sales Market Share Forecast by Country (2027-2032) Table 207. Latin America Gefitinib Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 208. Latin America Gefitinib Market Size by Country (2021-2026) & (US$ Million) Table 209. Latin America Gefitinib Market Share by Country (2021-2026) Table 210. Latin America Gefitinib Market Size Forecast by Country (2027-2032) & (US$ Million) Table 211. Latin America Gefitinib Market Share Forecast by Country (2027-2032) Table 212. Middle East and Africa Gefitinib Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 213. Middle East and Africa Gefitinib Sales by Country (2021-2026) & (k pcs) Table 214. Middle East and Africa Gefitinib Sales Market Share by Country (2021-2026) Table 215. Middle East and Africa Gefitinib Sales Forecast by Country (2027-2032) & (k pcs) Table 216. Middle East and Africa Gefitinib Sales Market Share Forecast by Country (2027-2032) Table 217. Middle East and Africa Gefitinib Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 218. Middle East and Africa Gefitinib Market Size by Country (2021-2026) & (US$ Million) Table 219. Middle East and Africa Gefitinib Market Share by Country (2021-2026) Table 220. Middle East and Africa Gefitinib Market Size Forecast by Country (2027-2032) & (US$ Million) Table 221. Middle East and Africa Gefitinib Market Share Forecast by Country (2027-2032) Table 222. Key Raw Materials Table 223. Raw Materials Key Suppliers Table 224. Gefitinib Distributors List Table 225. Gefitinib Customers List Table 226. Research Programs/Design for This Report Table 227. Authors List of This Report Table 228. Secondary Sources Table 229. Primary Sources List of Figures Figure 1. Gefitinib Image Figure 2. Global Gefitinib Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gefitinib Market Size (2021-2032) & (US$ Million) Figure 4. Global Gefitinib Sales (2021-2032) & (k pcs) Figure 5. 10 Tables/Box Image Figure 6. Global 10 Tables/Box Sales YoY Growth (2021-2032) & (k pcs) Figure 7. 30 Tables/Box Image Figure 8. Global 30 Tables/Box Sales YoY Growth (2021-2032) & (k pcs) Figure 9. 90 Tables/Box Image Figure 10. Global 90 Tables/Box Sales YoY Growth (2021-2032) & (k pcs) Figure 11. Global Gefitinib Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Gefitinib Market Share by Type 2025 VS 2032 Figure 13. North America Gefitinib Sales Market Share in Volume by Type in 2025 Figure 14. North America Gefitinib Sales Market Share in Value by Type in 2025 Figure 15. Europe Gefitinib Sales Market Share in Volume by Type in 2025 Figure 16. Europe Gefitinib Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Gefitinib Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Gefitinib Sales Market Share in Value by Type in 2025 Figure 19. Latin America Gefitinib Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Gefitinib Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Gefitinib Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Gefitinib Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Gefitinib Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Drug Center Image Figure 26. Global Drug Center Sales YoY Growth (2021-2032) & (k pcs) Figure 27. Hospital Image Figure 28. Global Hospital Sales YoY Growth (2021-2032) & (k pcs) Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (k pcs) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (k pcs) Figure 33. Global Gefitinib Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Gefitinib Market Share by Application 2025 VS 2032 Figure 35. North America Gefitinib Sales Market Share in Volume by Application in 2025 Figure 36. North America Gefitinib Sales Market Share in Value by Application in 2025 Figure 37. Europe Gefitinib Sales Market Share in Volume by Application in 2025 Figure 38. Europe Gefitinib Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Gefitinib Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Gefitinib Sales Market Share in Value by Application in 2025 Figure 41. Latin America Gefitinib Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Gefitinib Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Gefitinib Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Gefitinib Sales Market Share in Value by Application in 2025 Figure 45. North America Gefitinib Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 46. North America Gefitinib Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Gefitinib Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Gefitinib Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Gefitinib Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 50. Europe Gefitinib Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Gefitinib Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Gefitinib Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Gefitinib Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 54. Asia-Pacific Gefitinib Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Gefitinib Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Gefitinib Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Gefitinib Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 58. Latin America Gefitinib Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Gefitinib Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Gefitinib Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Gefitinib Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 62. Middle East and Africa Gefitinib Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Gefitinib Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Gefitinib Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Gefitinib Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Gefitinib Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • 10 Tables/Box
  • 30 Tables/Box
  • 90 Tables/Box
Applications
  • Drug Center
  • Hospital
  • Clinic
  • Others
Companies covered
  • Qilu Pharmaceutical
  • AstraZeneca
  • Zuventus Healthcare
  • United Biotech
  • Sichuan Xieli Pharmaceutical
  • Panacea Biotec
  • Nobel Ilac Sanayii Ve Ticaret
  • Nishchay Pharmaceuticals
  • Natco Pharma
  • Jodas Expoim
  • Hetero Drugs
  • Globela Pharma
  • Glenmark Pharmaceuticals
  • Flagship Biotech International
  • Ethypharm
  • Dr Reddy's Laboratories
  • Cipla
  • Celon Laboratories
  • Cadila Pharmaceuticals
  • Accure Labs

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gefitinib Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Gefitinib Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Gefitinib Market by Type
  6. 1.3.1 10 Tables/Box
  7. 1.3.2 30 Tables/Box
  8. 1.3.3 90 Tables/Box
  9. 1.4 Global Gefitinib Market Size by Type
  10. 1.4.1 Global Gefitinib Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Gefitinib Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Gefitinib Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Gefitinib Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Gefitinib Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Gefitinib Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Gefitinib Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Gefitinib Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Gefitinib Industry Trends
  2. 2.2 Gefitinib Industry Drivers
  3. 2.3 Gefitinib Industry Opportunities and Challenges
  4. 2.4 Gefitinib Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Gefitinib Revenue (2021-2026)
  2. 3.2 Global Top Players by Gefitinib Sales (2021-2026)
  3. 3.3 Global Top Players by Gefitinib Price (2021-2026)
  4. 3.4 Global Gefitinib Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Gefitinib Major Company Production Sites & Headquarters
  6. 3.6 Global Gefitinib Company, Product Type & Application
  7. 3.7 Global Gefitinib Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Gefitinib Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Gefitinib Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Gefitinib Tier 1, Tier 2, and Tier 3
4 Gefitinib Regional Status and Outlook
  1. 4.1 Global Gefitinib Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Gefitinib Historic Market Size by Region
  3. 4.2.1 Global Gefitinib Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Gefitinib Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Gefitinib Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Gefitinib Forecasted Market Size by Region
  7. 4.3.1 Global Gefitinib Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Gefitinib Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Gefitinib Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Gefitinib by Application
  1. 5.1 Gefitinib Market by Application
  2. 5.1.1 Drug Center
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Others
  6. 5.2 Global Gefitinib Market Size by Application
  7. 5.2.1 Global Gefitinib Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Gefitinib Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Gefitinib Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Gefitinib Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Gefitinib Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Gefitinib Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Gefitinib Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Gefitinib Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Qilu Pharmaceutical
  2. 6.1.1 Qilu Pharmaceutical Company Information
  3. 6.1.2 Qilu Pharmaceutical Business Overview
  4. 6.1.3 Qilu Pharmaceutical Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Qilu Pharmaceutical Gefitinib Product Portfolio
  6. 6.1.5 Qilu Pharmaceutical Recent Developments
  7. 6.2 AstraZeneca
  8. 6.2.1 AstraZeneca Company Information
  9. 6.2.2 AstraZeneca Business Overview
  10. 6.2.3 AstraZeneca Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 AstraZeneca Gefitinib Product Portfolio
  12. 6.2.5 AstraZeneca Recent Developments
  13. 6.3 Zuventus Healthcare
  14. 6.3.1 Zuventus Healthcare Company Information
  15. 6.3.2 Zuventus Healthcare Business Overview
  16. 6.3.3 Zuventus Healthcare Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Zuventus Healthcare Gefitinib Product Portfolio
  18. 6.3.5 Zuventus Healthcare Recent Developments
  19. 6.4 United Biotech
  20. 6.4.1 United Biotech Company Information
  21. 6.4.2 United Biotech Business Overview
  22. 6.4.3 United Biotech Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 United Biotech Gefitinib Product Portfolio
  24. 6.4.5 United Biotech Recent Developments
  25. 6.5 Sichuan Xieli Pharmaceutical
  26. 6.5.1 Sichuan Xieli Pharmaceutical Company Information
  27. 6.5.2 Sichuan Xieli Pharmaceutical Business Overview
  28. 6.5.3 Sichuan Xieli Pharmaceutical Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sichuan Xieli Pharmaceutical Gefitinib Product Portfolio
  30. 6.5.5 Sichuan Xieli Pharmaceutical Recent Developments
  31. 6.6 Panacea Biotec
  32. 6.6.1 Panacea Biotec Company Information
  33. 6.6.2 Panacea Biotec Business Overview
  34. 6.6.3 Panacea Biotec Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Panacea Biotec Gefitinib Product Portfolio
  36. 6.6.5 Panacea Biotec Recent Developments
  37. 6.7 Nobel Ilac Sanayii Ve Ticaret
  38. 6.7.1 Nobel Ilac Sanayii Ve Ticaret Company Information
  39. 6.7.2 Nobel Ilac Sanayii Ve Ticaret Business Overview
  40. 6.7.3 Nobel Ilac Sanayii Ve Ticaret Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Nobel Ilac Sanayii Ve Ticaret Gefitinib Product Portfolio
  42. 6.7.5 Nobel Ilac Sanayii Ve Ticaret Recent Developments
  43. 6.8 Nishchay Pharmaceuticals
  44. 6.8.1 Nishchay Pharmaceuticals Company Information
  45. 6.8.2 Nishchay Pharmaceuticals Business Overview
  46. 6.8.3 Nishchay Pharmaceuticals Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Nishchay Pharmaceuticals Gefitinib Product Portfolio
  48. 6.8.5 Nishchay Pharmaceuticals Recent Developments
  49. 6.9 Natco Pharma
  50. 6.9.1 Natco Pharma Company Information
  51. 6.9.2 Natco Pharma Business Overview
  52. 6.9.3 Natco Pharma Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Natco Pharma Gefitinib Product Portfolio
  54. 6.9.5 Natco Pharma Recent Developments
  55. 6.10 Jodas Expoim
  56. 6.10.1 Jodas Expoim Company Information
  57. 6.10.2 Jodas Expoim Business Overview
  58. 6.10.3 Jodas Expoim Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Jodas Expoim Gefitinib Product Portfolio
  60. 6.10.5 Jodas Expoim Recent Developments
  61. 6.11 Hetero Drugs
  62. 6.11.1 Hetero Drugs Company Information
  63. 6.11.2 Hetero Drugs Business Overview
  64. 6.11.3 Hetero Drugs Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Hetero Drugs Gefitinib Product Portfolio
  66. 6.11.5 Hetero Drugs Recent Developments
  67. 6.12 Globela Pharma
  68. 6.12.1 Globela Pharma Company Information
  69. 6.12.2 Globela Pharma Business Overview
  70. 6.12.3 Globela Pharma Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Globela Pharma Gefitinib Product Portfolio
  72. 6.12.5 Globela Pharma Recent Developments
  73. 6.13 Glenmark Pharmaceuticals
  74. 6.13.1 Glenmark Pharmaceuticals Company Information
  75. 6.13.2 Glenmark Pharmaceuticals Business Overview
  76. 6.13.3 Glenmark Pharmaceuticals Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Glenmark Pharmaceuticals Gefitinib Product Portfolio
  78. 6.13.5 Glenmark Pharmaceuticals Recent Developments
  79. 6.14 Flagship Biotech International
  80. 6.14.1 Flagship Biotech International Company Information
  81. 6.14.2 Flagship Biotech International Business Overview
  82. 6.14.3 Flagship Biotech International Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Flagship Biotech International Gefitinib Product Portfolio
  84. 6.14.5 Flagship Biotech International Recent Developments
  85. 6.15 Ethypharm
  86. 6.15.1 Ethypharm Company Information
  87. 6.15.2 Ethypharm Business Overview
  88. 6.15.3 Ethypharm Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Ethypharm Gefitinib Product Portfolio
  90. 6.15.5 Ethypharm Recent Developments
  91. 6.16 Dr Reddy's Laboratories
  92. 6.16.1 Dr Reddy's Laboratories Company Information
  93. 6.16.2 Dr Reddy's Laboratories Business Overview
  94. 6.16.3 Dr Reddy's Laboratories Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Dr Reddy's Laboratories Gefitinib Product Portfolio
  96. 6.16.5 Dr Reddy's Laboratories Recent Developments
  97. 6.17 Cipla
  98. 6.17.1 Cipla Company Information
  99. 6.17.2 Cipla Business Overview
  100. 6.17.3 Cipla Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Cipla Gefitinib Product Portfolio
  102. 6.17.5 Cipla Recent Developments
  103. 6.18 Celon Laboratories
  104. 6.18.1 Celon Laboratories Company Information
  105. 6.18.2 Celon Laboratories Business Overview
  106. 6.18.3 Celon Laboratories Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Celon Laboratories Gefitinib Product Portfolio
  108. 6.18.5 Celon Laboratories Recent Developments
  109. 6.19 Cadila Pharmaceuticals
  110. 6.19.1 Cadila Pharmaceuticals Company Information
  111. 6.19.2 Cadila Pharmaceuticals Business Overview
  112. 6.19.3 Cadila Pharmaceuticals Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Cadila Pharmaceuticals Gefitinib Product Portfolio
  114. 6.19.5 Cadila Pharmaceuticals Recent Developments
  115. 6.20 Accure Labs
  116. 6.20.1 Accure Labs Company Information
  117. 6.20.2 Accure Labs Business Overview
  118. 6.20.3 Accure Labs Gefitinib Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Accure Labs Gefitinib Product Portfolio
  120. 6.20.5 Accure Labs Recent Developments
7 North America by Country
  1. 7.1 North America Gefitinib Sales by Country
  2. 7.1.1 North America Gefitinib Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Gefitinib Sales by Country (2021-2026)
  4. 7.1.3 North America Gefitinib Sales Forecast by Country (2027-2032)
  5. 7.2 North America Gefitinib Market Size by Country
  6. 7.2.1 North America Gefitinib Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Gefitinib Market Size by Country (2021-2026)
  8. 7.2.3 North America Gefitinib Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Gefitinib Sales by Country
  2. 8.1.1 Europe Gefitinib Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Gefitinib Sales by Country (2021-2026)
  4. 8.1.3 Europe Gefitinib Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Gefitinib Market Size by Country
  6. 8.2.1 Europe Gefitinib Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Gefitinib Market Size by Country (2021-2026)
  8. 8.2.3 Europe Gefitinib Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Gefitinib Sales by Country
  2. 9.1.1 Asia-Pacific Gefitinib Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Gefitinib Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Gefitinib Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Gefitinib Market Size by Country
  6. 9.2.1 Asia-Pacific Gefitinib Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Gefitinib Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Gefitinib Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Gefitinib Sales by Country
  2. 10.1.1 South America Gefitinib Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Gefitinib Sales by Country (2021-2026)
  4. 10.1.3 South America Gefitinib Sales Forecast by Country (2027-2032)
  5. 10.2 South America Gefitinib Market Size by Country
  6. 10.2.1 South America Gefitinib Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Gefitinib Market Size by Country (2021-2026)
  8. 10.2.3 South America Gefitinib Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Gefitinib Sales by Country
  2. 11.1.1 Middle East and Africa Gefitinib Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Gefitinib Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Gefitinib Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Gefitinib Market Size by Country
  6. 11.2.1 Middle East and Africa Gefitinib Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Gefitinib Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Gefitinib Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Gefitinib Value Chain Analysis
  2. 12.1.1 Gefitinib Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Gefitinib Production Mode & Process
  7. 12.2 Gefitinib Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Gefitinib Distributors
  10. 12.2.3 Gefitinib Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst